452|9893|Public
25|$|Low-density {{lipoprotein}} (LDL) {{are one of}} {{the five}} major groups of lipoprotein which transport all fat molecules around the body in the extracellular water. These groups, from least dense, compared to surrounding water, (largest particles) to most dense (smallest particles), are chylomicrons (aka ULDL by the overall density naming convention), <b>very</b> <b>low-density</b> <b>lipoprotein</b> (VLDL), intermediate-density lipoprotein (IDL), low-density lipoprotein and high-density lipoprotein (HDL). LDL delivers fat molecules to the cells and can drive the progression of atherosclerosis if they become oxidized within the walls of arteries.|$|E
25|$|It reduces {{secondary}} outcomes {{associated with}} atherosclerosis, such as low density lipoprotein cholesterol (LDL), <b>very</b> <b>low-density</b> <b>lipoprotein</b> cholesterol (VLDL-C), and triglycerides (TG), but increases high density lipoprotein cholesterol (HDL). Despite {{the importance of}} other cardiovascular risk factors, high HDL was associated with fewer cardiovascular events independent of LDL reduction. Other effects include anti-thrombotic and vascular inflammation, improving endothelial function, and plaque stability. Adipokines are the adipocytes’ produced mediators. Some adipokines such as tumor necrosis factor (TNF)-a, interleukins and chemokines, have pro-inflammatory effect and some others such as adiponectin have anti-inflammatory effect that regulates inflammatory process, decrease vascular progression and atherosclerosis.|$|E
50|$|Lomitapide {{inhibits}} the microsomal triglyceride transfer protein (MTP or MTTP) {{which is}} necessary for <b>very</b> <b>low-density</b> <b>lipoprotein</b> (VLDL) assembly and secretion in the liver.|$|E
50|$|At this point, the fats {{are in the}} {{bloodstream}} {{in the form of}} chylomicrons. Once in the blood, chylomicrons are subject to delipidation by lipoprotein lipase. Eventually, enough lipid has been lost and additional apolipoproteins gained, that the resulting particle (now referred to as a chylomicron remnant) can be taken up by the liver. From the liver, the fat released from chylomicron remnants can be re-exported to the blood as the triglyceride component of <b>very</b> <b>low-density</b> <b>lipoproteins.</b> <b>Very</b> <b>low-density</b> <b>lipoproteins,</b> also subject to delipidation by vascular lipoprotein lipase, delivers fats to tissues throughout the body and, in particular, the released fatty acids can be stored in adipose cells as triglycerides. As triglycerides are lost from <b>very</b> <b>low-density</b> <b>lipoproteins,</b> the lipoprotein particle becomes smaller and denser (since protein is denser than lipid) and ultimately becomes <b>low-density</b> <b>lipoproteins.</b> A great deal has been written about <b>low-density</b> <b>lipoproteins</b> because they are thought to be atherogenic.|$|R
50|$|<b>Very</b> <b>low-density</b> <b>lipoproteins</b> {{transport}} endogenous triglycerides, phospholipids, cholesterol, and cholesteryl esters. It {{functions as}} the body's internal transport mechanism for lipids. In addition it serves for long-range transport of hydrophobic intercellular messengers, like the morphogen Indian hedgehog (protein).|$|R
50|$|<b>Very</b> <b>low-density</b> <b>lipoproteins</b> and <b>low-density</b> <b>lipoproteins</b> {{interfere}} with the quorum sensing system that upregulates genes required for invasive Staphylococcus aureus infection. The mechanism of antagonism entails binding ApoB, to a S. aureus autoinducer pheromone, preventing signaling through its receptor. Mice deficient in ApoB {{are more susceptible to}} invasive bacterial infection.|$|R
5000|$|Lipid Panel: low {{high-density}} lipoprotein (HDL) < 10 mg/dL, elevated <b>very</b> <b>low-density</b> <b>lipoprotein</b> (VLDL) and triglycerides, high plasma unesterified cholesterol, and low plasma cholesterol ester ...|$|E
50|$|Alpha-1-acid {{glycoprotein}} {{has been}} identified as one of four potentially useful circulating biomarkers for estimating the five-year risk of all-cause mortality (the other three are albumin, <b>very</b> <b>low-density</b> <b>lipoprotein</b> particle size, and citrate).|$|E
50|$|Remnant cholesterol, {{also known}} as remnant {{lipoprotein}}, is a very atherogenic lipoprotein composed primarily of <b>very</b> <b>low-density</b> <b>lipoprotein</b> (VLDL) and intermediate-density lipoprotein (ILD). Stated another way, remnant cholesterol is all plasma cholesterol that is not LDL cholesterol or HDL cholesterol.|$|E
5000|$|Hyperlipidaemia {{is caused}} by an {{increase}} in the synthesis of low and <b>very</b> <b>low-density</b> <b>lipoproteins</b> in the liver that are responsible for the transport of cholesterol and triglycerides. There is also an increase in the hepatic synthesis of cholesterol.|$|R
50|$|Apolipoprotein B {{can exist}} in two forms: B-100 and B-48. Apolipoprotein B-100 is present on several <b>lipoproteins,</b> {{including}} <b>very</b> <b>low-density</b> <b>lipoproteins</b> (VLDL), intermediate density lipoproteins (IDL) and low density lipoproteins (LDL), and can assemble VLDL {{particles in the}} liver. Apolipoprotein B-100 {{has been linked to}} the development of atherosclerosis.|$|R
40|$|Objective: {{to study}} the regularities of {{postpartum}} blood biochemical changes in varying severity gestosis. Subjects and methods: thirty-five females were examined in the puerperium. Blood was taken on postpartum days 1 and 3 — 4. The parameters of hepatic and renal function and lipid parameters were determined. Results. Higher levels of creatitine and urea and a more pronounced increase in the concentration of triglycerides and <b>very</b> <b>low-density</b> <b>lipoproteins</b> were observed in moderate gestosis than in normal physiological pregnancy. All the examinees were recorded to have low total protein levels within the first 24 hours after labor. Parturient women with moderate gestosis showed negative changes in protein concentrations throughout the study. Severe gestosis was characterized by multiple increases in bilirubin concentrations and, in case of death, these are also added by higher alanine aminotransferase and aspartate aminotransferase activities. Conclusion. Hypoproteinemia, hypocalcemia, elevated levels of triglycerides and <b>very</b> <b>low-density</b> <b>lipoproteins</b> and a simultaneous decrease in high-density lipoproteins are preserved in moderate gestosis in the early puerperium. </p...|$|R
5000|$|Lipid Panel: low {{high-density}} lipoprotein (HDL) < 10 mg/dL, elevated <b>very</b> <b>low-density</b> <b>lipoprotein</b> (VLDL) and triglycerides, high plasma unesterified cholesterol in HDL particles, and low cholesterol ester in HDL particles but normal levels in low-density lipoprotein (LDL) and VLDL particles ...|$|E
50|$|Low-density {{lipoprotein}} (LDL) {{is one of}} {{the five}} major groups of lipoprotein. These groups, from least dense, compared to surrounding water, (largest particles) to most dense (smallest particles), are chylomicrons, <b>very</b> <b>low-density</b> <b>lipoprotein</b> (VLDL), intermediate-density lipoprotein (IDL), low-density lipoprotein and high-density lipoprotein (HDL).|$|E
50|$|Mipomersen binds to the {{messenger}} RNA coding for apolipoprotein B-100 (ApoB-100), a protein {{that is the}} main component of low-density lipoprotein (LDL) and <b>very</b> <b>low-density</b> <b>lipoprotein</b> (VLDL). As a consequence, the RNA is degraded by the enzyme ribonuclease H, and ApoB-100 is not translated.|$|E
40|$|Paradoxically, {{meta-analysis}} of human randomized controlled trials revealed that natural but not synthetic α-tocopherol supplementation significantly increases all-cause mortality at 95 % confidence interval. The root cause was that natural α-tocopherol supplementation significantly depressed bioavailability of {{other forms of}} vitamin E that have better chemo-prevention capability. Meta-analysis outcome demonstrated flaws {{in the understanding of}} vitamin E. Reinterpretation of reported data provides plausible explanations to several important observations. While α-tocopherol is almost exclusively secreted in chylomicrons, enterocytes secrete tocotrienols in both chylomicrons and small high-density lipoproteins. Vitamin E secreted in chylomicrons is discriminately repacked by α-tocopherol transfer protein into nascent <b>very</b> <b>low-density</b> <b>lipoproteins</b> in the liver. Circulating <b>very</b> <b>low-density</b> <b>lipoproteins</b> undergo delipidation to form intermediate-density <b>lipoproteins</b> and <b>low-density</b> <b>lipoproteins.</b> Uptake of vitamin E in intermediate-density <b>lipoproteins</b> and <b>low-density</b> <b>lipoproteins</b> takes place at various tissues via <b>low-density</b> <b>lipoproteins</b> receptor–mediated endocytosis. Small high-density lipoproteins can deliver tocotrienols upon maturation to peripheral tissues independent of α-tocopherol transfer protein action, and uptake of vitamin E takes place at selective tissues by scavenger receptor–mediated direct vitamin E uptake. Dual absorption pathways for tocotrienols are consistent with human and animal studies. α-Tocopherol depresses the bioavailability of α-tocotrienol and has antagonistic effect on tocotrienols in chemo-prevention against degenerative diseases. Therefore, it is an undesirable component for chemo-prevention. Future research directions should be focused on tocotrienols, preferably free from α-tocopherol, for optimum chemo-prevention and benefits to mankind...|$|R
5000|$|Lipoprotein lipase (LPL) (...) is {{a member}} of the lipase gene family, which {{includes}} pancreatic lipase, hepatic lipase, and endothelial lipase. It is a water-soluble enzyme that hydrolyzes triglycerides in lipoproteins, such as those found in chylomicrons and <b>very</b> <b>low-density</b> <b>lipoproteins</b> (VLDL), into three free fatty acids and one glycerol molecule. It is also involved in promoting the cellular uptake of chylomicron remnants, cholesterol-rich lipoproteins, and free fatty acids. LPL requires ApoC-II as a cofactor.|$|R
40|$|Binding {{of various}} 125 I-lipoproteins to hepatic receptors was studied on cultured human {{hepatoma}} cells (Hep G 2). Chylomicrons, isolated from a chylothorax, chylomicron remnants, hypertriglyceridemic <b>very</b> <b>low-density</b> <b>lipoproteins,</b> normotriglyceridemic <b>very</b> <b>low-density</b> <b>lipoproteins</b> (NTG-VLDL), their remnants, <b>low-density</b> <b>lipoproteins</b> (LDL), and HDL-E (an Apo E-rich high-density lipoprotein {{isolated from the}} plasma of a patient with primary biliary cirrhosis) were bound by high-affinity receptors. Chylomicron remnants and HDL-E were bound with the highest affinity. The results, obtained from competitive binding experiments, {{are consistent with the}} existence of two distinct receptors on Hep G 2 cells: (a) a remnant receptor capable of high-affinity binding of triglyceride-rich lipoproteins and HDL-E, but not of Apo E free LDL, and (b) a LDL receptor capable of high-affinity binding of LDL, NTG-VLDL, and HDL-E. Specific binding of Apo E-free LDL was completely abolished in the presence of 3 mM EDTA, indicating that binding to the LDL receptor is calcium dependent. Specific binding of chylomicron remnants was not inhibited by the presence of even 10 mM EDTA. Preincubation of the Hep G 2 cells in lipoprotein-containing medium resulted in complete suppression of LDL receptors but did not affect the remnant receptors. Hep G 2 cells seem to be a suitable model for the study of hepatic receptors for lipoprotein in man...|$|R
50|$|Omega-3 {{carboxylic}} acids, {{like other}} omega-3 fatty acid based drugs, appears to reduce production of triglycerides in the liver, {{and to enhance}} clearance of triglycerides from circulating <b>very</b> <b>low-density</b> <b>lipoprotein</b> (VLDL) particles; {{the way it does}} that is not clear, but potential mechanisms include increased breakdown of fatty acids; inhibition of diglyceride acyltransferase which is involved in biosynthesis of triglycerides in the liver; and increased activity of lipoprotein lipase in blood.|$|E
50|$|Chylomicrons (from the Greek chylo, meaning milky fluid, and micron, meaning small particle) are {{lipoprotein}} {{particles that}} consist of triglycerides (85-92%), phospholipids (6-12%), cholesterol (1-3%), and proteins (1-2%).They transport dietary lipids from the intestines to other {{locations in the}} body. Chylomicrons {{are one of the}} five major groups of lipoproteins: chylomicrons (a.k.a. ULDL ultra low-density lipoprotein relative to surrounding water), <b>very</b> <b>low-density</b> <b>lipoprotein,</b> intermediate-density lipoprotein, low-density lipoprotein, high-density lipoprotein, that enable fats and cholesterol to move within the water-based solution of the bloodstream.|$|E
5000|$|Omega-3 acid ethyl esters, {{like other}} omega-3 fatty acid based drugs, appears to reduce {{production}} of triglycerides in the liver, {{and to enhance}} clearance of triglycerides from circulating <b>very</b> <b>low-density</b> <b>lipoprotein</b> (VLDL) particles; {{the way it does}} that is not clear, but potential mechanisms include increased breakdown of fatty acids; inhibition of diglyceride acyltransferase which is involved in biosynthesis of triglycerides in the liver; and increased activity of lipoprotein lipase in blood. [...] They may interfere with lipid production due to being poor substrates for the enzymes that create triglycerides.|$|E
40|$|To {{evaluate}} {{the effects of}} dietary phospholipids on plasma lipoproteins in the postprandial phase six normolipidemic men were fed alternatively a test meal rich in phosphatidylcholine and a control meal low in phosphatidylcholine. Plasma <b>very</b> <b>low-density</b> <b>lipoproteins,</b> <b>low-density</b> <b>lipoproteins,</b> and high-density lipoproteins were isolated at 2, 4 and 6 h after the meals. The changes in lipoprotein cholesterol, triacylglycerol, and phospholipid after feeding the phospholipid-rich meal were indistinguishable from those after the low-phospholipid meal. The phospholipid composition in high-density lipoproteins was also unchanged. The amount of phosphatidylcholine used in this trial was approximately 10 -fold higher than that found in the normal Swedish diet. It is therefore concluded that the normal dietary intake of phosphatidylcholine has little influence on the plasma lipoprotein parameters measured in the present study...|$|R
50|$|Evacetrapib {{was a drug}} under {{development}} by Eli Lilly & Company (investigational name LY2484595) that inhibits cholesterylester transfer protein (CETP inhibitor). CETP collects triglycerides from <b>very</b> <b>low-density</b> <b>lipoproteins</b> (VLDL) or <b>low-density</b> <b>lipoproteins</b> (LDL) and exchanges them for cholesteryl esters from high-density lipoproteins (HDL), and vice versa, but primarily increasing high-density <b>lipoprotein</b> and lowering <b>low-density</b> <b>lipoprotein.</b> It is thought that modifying lipoprotein levels modifies the risk of cardiovascular disease. The first CETP inhibitor, torcetrapib, was unsuccessful because it increased levels of the hormone aldosterone and increased blood pressure, which led to excess cardiac events when it was studied. Evacetrapib {{does not have the}} same effect. When studied in a small clinical trial in people with elevated LDL and low HDL, significant improvements were noted in their lipid profile.|$|R
30|$|Caco- 2 cells act {{similarly}} as cell {{in animals}} when stimulated by fatty acid. van Greevenbroek et al. {{suggested that the}} incorporation of long-chain unsaturated fatty acids (e.g., oleic acid and linoleic acid) into the Caco- 2 cells stimulate the secretion of <b>very</b> <b>low-density</b> <b>lipoproteins</b> (VLDL) and chylomicrons. In contrast, administration of saturated fatty acids primarily secretes intermediate- and <b>low-density</b> <b>lipoproteins</b> (IDL and LDL) [27]. Similar findings of increasing chylomicron secretion by the long-chain fatty acids were also reported by Caliph et al. in animal model [28]. In the present investigation, the long-chain fatty acids (Compritol 888 ATO® and oleic acid) used {{in the preparation of}} the HVD-NLCs may also stimulate the secretion of chylomicron, and hence increase the cellular uptake of the model drug.|$|R
50|$|It reduces {{secondary}} outcomes {{associated with}} atherosclerosis, such as low density lipoprotein cholesterol (LDL), <b>very</b> <b>low-density</b> <b>lipoprotein</b> cholesterol (VLDL-C), and triglycerides (TG), but increases high density lipoprotein cholesterol (HDL). Despite {{the importance of}} other cardiovascular risk factors, high HDL was associated with fewer cardiovascular events independent of LDL reduction. Other effects include anti-thrombotic and vascular inflammation, improving endothelial function, and plaque stability. Adipokines are the adipocytes’ produced mediators. Some adipokines such as tumor necrosis factor (TNF)-a, interleukins and chemokines, have pro-inflammatory effect and some others such as adiponectin have anti-inflammatory effect that regulates inflammatory process, decrease vascular progression and atherosclerosis.|$|E
50|$|All animals {{regulate}} the glucose concentration in their extracellular fluids. In mammals the primary sensor {{is situated in}} the beta cells of the pancreatic islets. The beta cells respond to {{a rise in the}} blood sugar level by secreting insulin into the blood, and simultaneously inhibiting their neighboring alpha cells from secreting glucagon into the blood. This combination (high blood insulin levels and low glucagon levels) act on effector tissues, chief of which are the liver, fat cells and muscle cells. The liver is inhibited from producing glucose, taking it up instead, and converting it to glycogen and triglycerides. The glycogen is stored in the liver, but the triglycerides are secreted into the blood as <b>very</b> <b>low-density</b> <b>lipoprotein</b> (VLDL) particles which are taken up by adipose tissue, there to be stored as fats. The fat cells take up glucose through special glucose transporters (GLUT4), whose numbers in the cell wall are increased as a direct effect of insulin acting on these cells. The glucose that enters the fat cells in this manner is converted into triglycerides (via the same metabolic pathways as are used by the liver) and then stored in those fat cells together with the VLDL-derived triglycerides that were made in the liver. Muscle cells also take glucose up through insulin-sensitive GLUT4 glucose channels, and convert it into muscle glycogen.|$|E
40|$|We {{characterized}} the lipo-protein abnormalities encountered {{in a series}} of 45 nonnephrotic uremic children with various degrees of chronic renal insufficiency. A mild hypertriglyceridemia associated with decreased serum high-density lipoprotein cholesterol levels was confirmed. The correlation between high-density lipoprotein cholesterol and creatinine clearance showed a power behavior with a marked decrease in high-density lipoprotein cholesterol below a creatinine clearance value of 40 ml/min/ 1. 73 m 2. A number of uremic children accumulate an abnormal population of <b>very</b> <b>low-density</b> <b>lipoprotein</b> particles in their plasma. On agarose gel electrophoresis these particles migrate as a slow moving pre-β band and are clearly distinguished from the regular fast moving pre-β <b>very</b> <b>low-density</b> <b>lipoprotein</b> band. This electrophoretic phenomenon has been called double pre-β lipoproteinoproteinemia. The prevalence of double pre-β lipoproteinemia increased significantly with the degree of impairment of renal function, reaching highest figures in patients on hemodialysis. Accordingly, the <b>very</b> <b>low-density</b> <b>lipoprotein</b> cholesterol/triglyceride ratio also was significantly increased. The double pre-β lipoproteinemia phenomenon was not detected in any of the control, nonuremic subjects. The clinical importance of double pre-β lipoproteinemia in uremic plasma is related to its possible atherogenic role...|$|E
40|$|AbstractThe role of heparin-releasable hepatic endothelial lipase (HL) {{in human}} plasma {{lipoprotein}} metabolism was investigated {{by examining the}} effects of intravenous infusion of heparin (180 units/kg over 2 h) in 8 subjects with primary extrahepatic lipoprotein lipase deficiency. In addition to reducing the triglyceride concentration in <b>very</b> <b>low-density</b> <b>lipoproteins,</b> heparin-induced release of HL reduced the phopholipid and protein concentrations in the HDL 2 subclass of high-density lipoprotein (by 28 % and 36 % respectively, mean values) and simultaneously increased the HDL 3 phospholipid concentration (by 23 %), providing the first in vivo evidence for a function of HL in the interconversion of the major HDL subfractions in man...|$|R
40|$|Atherosclerotic {{cardiovascular}} (CV) {{disease is}} the leading cause of death of type 2 diabetic patients, 1 possibly ow-ing to its refractoriness to glucose control. 2 – 4 Insulin resistance can also account for the increased vulnerability of diabetic pa-tients to atherosclerosis, but its pathogenetic mechanism is not completely understood, and is likely to involve multiple target organs of insulin action. 5 In This Issue, see p 977 Editorial, see p 978 In the liver, for example, alterations of insulin receptor (InsR) signaling result in changes of hepatocellular triglyceride con-tent and assembly into or export as apolipoprotein B (ApoB) – containing, <b>very</b> <b>low-density</b> <b>lipoproteins</b> 6, 7 that are typically elevated in the plasma of type 2 diabetic patients. 8 In addition, hepatic InsR signaling also regulates <b>low-density</b> <b>lipoproteins</b> re-ceptor turnover, 9 possibly contributing to the lower than expect...|$|R
40|$|T he biogenesis of <b>very</b> <b>low-density</b> <b>lipoproteins</b> (VLDLs) {{and their}} {{secretion}} into the circulatory system by the liver {{is a complex}} but highly controlled process that {{plays an important role}} in overall lipid homeostasis. Enhanced produc-tion of VLDLs and their eventual secretion into the circulatory system constitute one of the major risk factors for the develop-ment of atherosclerosis. 1, 2 Higher concentrations of VLDLs in the blood are often translated into higher levels of atherogenic particles, <b>low-density</b> <b>lipoproteins</b> (LDLs). Interestingly, the production of VLDLs needs to be synchronized with their secretion to avoid adverse consequences such as hepatic steato-sis. 3 These 2 clinical scenarios arising from abnormal assembly and secretion of VLDLs underscore their importance. From their production to secretion, VLDLs go through several com-plex intracellular processes that determine the rate of secre-tion in the circulation. A number of factors have been wel...|$|R
40|$|Macular {{telangiectasia}} (MacTel) is a vision-threatening retinal {{disease with}} unknown pathogenesis and no approved treatment. <b>Very</b> <b>low-density</b> <b>lipoprotein</b> receptor mutant mice (Vldlr−/−) exhibit critical features of MacTel, such as retinal neovascularization and photoreceptor degeneration. In this study, the authors evaluated the therapeutic potential of resveratrol, a plant polyphenol, in Vldlr−/− mice {{as a model}} for MacTel...|$|E
40|$|Peculiarities {{of blood}} lipids in {{children}} with metabolic syndrome were studied. We observed 139 children aged 9 to 18 years, who formed two groups: 1 st group — 85 children with metabolic syndrome on the background of abdominal obesity, 2 nd group — 54 children with normal body weight. We have carried out anthropometry, defined levels of total cholesterol, high-density lipoprotein cholesterol, low-density lipoprotein cholesterol, <b>very</b> <b>low-density</b> <b>lipoprotein</b> cholesterol, triglycerides, blood pressure measured. It is found that signs of dyslipidemia were significantly elevated levels of total cholesterol, low-density lipoprotein cholesterol, <b>very</b> <b>low-density</b> <b>lipoprotein</b> cholesterol, triglycerides and ratio of non-high-density lipoprotein cholesterol, total cholesterol/high-density lipoprotein cholesterol, atherogenic index, which should be used as markers in the diagnosis of metabolic syndrome in children. Relative increase of high-density lipoprotein cholesterol fractions, possibly, must be considered as compensatory reaction {{in response to an}} increase of proatherogenic cholesterol fractions with a view to their normalization...|$|E
40|$|BackgroundIn {{cirrhosis}} {{the production}} of cholesterol and lipoproteins is altered. ObjectiveEvaluate the lipid profile by measuring total cholesterol, <b>very</b> <b>low-density</b> <b>lipoprotein,</b> low-density lipoprotein, high-density lipoprotein and triglyceride levels in patients with cirrhosis caused by alcoholism and/or hepatitis C virus infection and determine its association with Child-Pugh and MELD scores. MethodsCross-sectional retrospective study of patients treated at the outpatient clinic in Porto Alegre, Brazil, from 2006 to 2010. ResultsIn total, 314 records were reviewed, and 153 (48. 7 %) met the inclusion criteria, of which 82 (53. 6 %) had cirrhosis that was due to hepatitis C virus infection, 50 (32. 7 %) were due to alcoholism, and 21 (13. 7 %) were due to alcoholism and hepatitis C virus infection. The total cholesterol levels diminished with a Child-Pugh progression (P 20 was associated with lower total cholesterol levels (< 100 mg/dL; P< 0. 001), <b>very</b> <b>low-density</b> <b>lipoprotein</b> (< 16 mg/dL; P= 0. 006), and low-density lipoprotein (< 70 mg/dL; P= 0. 003). Inverse and statistically significant correlations were observed between Child-Pugh and all the lipid fractions analyzed (P< 0. 001). The increase in MELD was inversely correlated with reduced levels intotal cholesterol (P< 0. 001), high-density lipoprotein (P< 0. 001), low-density lipoprotein (P< 0. 001), <b>very</b> <b>low-density</b> <b>lipoprotein</b> (P= 0. 030) and triglyceride (P= 0. 003). ConclusionA reduction in the lipid profile in patients with cirrhosis due to hepatitis C virus infection and/or alcoholism {{was significantly associated with}} the Child-Pugh and MELD prognostic markers. These results suggest that the lipid profile may be used as a tool to assist in evaluating liver disease...|$|E
40|$|Abstract INTRODUCTION : The human T-lymphotropic virus- 1 (HTLV- 1) is {{associated}} with chronic inflammatory diseases such as HTLV- 1 -associated myelopathy/tropical spastic paraparesis (HAM/TSP), a chronic inflammatory disease. Disturbances in lipid metabolism are involved in inflammatory and demyelinating diseases. METHODS : Plasma levels of triglycerides, total cholesterol, and fractions of HTLV- 1 -infected individuals of both sexes with different clinical progressions were determined. RESULTS : Elevated levels of triglyceride and <b>very</b> <b>low-density</b> <b>lipoproteins</b> (VLDL) were exclusively detected in HTLV- 1 -infected women from asymptomatic and HAM/TSP groups compared with uninfected individuals (p = 0. 02). CONCLUSIONS : Elevated triglyceride and VLDL levels in HTLV- 1 -infected women {{may be related to}} the predominance of HAM/TSP in women...|$|R
40|$|The {{activity}} of 3 -hydroxy- 3 -methylglutaryl coenzyme A reductase (EC 1. 1. 1. 34), the rate-limiting enzyme of hepatic cholesterol biosynthesis, is suppressed in human fibroblasts cultured {{in the presence}} of serum. This enzyme activity increases by more than 10 -fold after the removal of serum from the medium. The rise in enzyme activity requires de novo protein synthesis and is not accompanied by changes in the activities of several other cellular enzymes. The factor responsible for the suppression of 3 -hydroxy- 3 -methylglutaryl coenzyme A reductase activity in cultured fibroblasts is present in the sera of at least four mammalian species, and in human serum it is found in the <b>low-density</b> <b>lipoproteins.</b> Human high-density <b>lipoproteins,</b> <b>very</b> <b>low-density</b> <b>lipoproteins</b> from chicken egg yolk, and the fraction of human serum containing no lipoproteins do not suppress the {{activity of}} 3 -hydroxy- 3 -methylglutaryl coenzyme A reductase...|$|R
30|$|Bet showed {{comparable}} {{effect to}} VC and could replace {{it as an}} anti-stress agent without any loss in the productive traits of breeder hens. Furthermore, Bet was more effective than VE and was equal or {{better than the other}} combinations of the supplements. Similarly, 0.1  % Bet increased egg production by 10  % through stimulation the secretion in the anterior pituitary of the follicle stimulating hormone and luteinizing hormone (Zou and Feng 2002) and dietary Bet at 0.2  % improved laying rate in heat- stressed layers (Rue et al. 2002). Similarly, <b>very</b> <b>low-density</b> <b>lipoproteins</b> and vitellogenin the precursors of egg yolk were significantly decreased due to heat stress (Bollengier-Lee et al. 1999) and increased by Bet supplementation at 0.06  % (Lu and Zou 2006).|$|R
